Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times

被引:43
作者
Ashwell, SG [1 ]
Gebbie, J [1 ]
Home, PD [1 ]
机构
[1] Univ Newcastle Upon Tyne, Newcastle Diabet Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
关键词
glargine; insulin glargine; timing; Type; 1; diabetes;
D O I
10.1111/j.1464-5491.2005.01726.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To compare blood glucose control when insulin glargine is given at lunch-time, dinner-time, and bed-time in people with Type 1 diabetes using insulin lispro at meal-times. Methods In this 16-week, three-way, cross-over study, 23 people with Type 1 diabetes were randomized to insulin glargine injection at lunch-time (L) [mean 12.37 +/- 00.34 (+/- SD) h], dinner-time (D) (18.12 +/- 00.40 h), or bed-time (B) (22.29 +/- 00.40 h), each plus meal-time insulin lispro. Each 4-week treatment period concluded with a 24-h inpatient metabolic profile. Results Insulin doses, HbA(1c), and fructosamine concentration did not differ between treatment periods. Pre-breakfast self-monitored blood glucose (SMBG) concentration was higher with injection of glargine at lunch-time than at other times [L: 9.2 +/- 0.3 (+/- SE) vs. D: 8.2 +/- 0.3 or B: 8.0 +/- 0.3 mmol/l, P = 0.016], as probably was pre-lunch SMBG (L: 8.6 +/- 0.7 vs. D: 6.4 +/- 0.7 or B: 6.4 +/- 0.8 mmol/l, P = 0.051). Pre-dinner SMBG level was higher with dinner-time glargine than other injection times (D: 9.4 +/- 0.9 vs. L: 4.9 +/- 0.9 or B: 7.4 +/- 1.1 mmol/l, P = 0.007). For 22.00 to 02.00 h, mean inpatient plasma glucose concentration was higher with injection of glargine at bed-time than other times (B: 9.1 +/- 0.6 vs. L: 7.8 +/- 0.6 or D: 6.7 +/- 0.6 mmol/l, P = 0.023). Plasma free insulin concentration was lower at the end of the afternoon with dinner-time glargine than other injection times (D: 11.5 +/- 1.4 vs. L: 20.2 +/- 1.3 or B: 16.5 +/- 1.3 mU/l, P < 0.001). Frequency of hypoglycaemia was not different, but timing of hypoglycaemia differed between treatment periods. Conclusions Blood glucose levels rise around the time of injection of insulin glargine whether given at lunch-time, dinner-time or bed-time. Bed-time injection leads to hyperglycaemia in the early part of the night which is improved by giving insulin glargine at lunch-time or dinner-time.
引用
收藏
页码:46 / 52
页数:7
相关论文
共 14 条
  • [1] The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients
    Ahmed, ABE
    Home, PD
    [J]. DIABETES CARE, 1998, 21 (01) : 32 - 37
  • [2] Ashwell S, 2003, DIABETES, V52, pA442
  • [3] Diabetes treatment satisfaction questionnaire
    Bradley, C
    [J]. DIABETES CARE, 1999, 22 (03) : 530 - 532
  • [4] Bradley C., 1994, Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice, P111
  • [5] A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes
    Hamann, A
    Matthaei, S
    Rosak, C
    Silvestre, L
    [J]. DIABETES CARE, 2003, 26 (06) : 1738 - 1744
  • [6] Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo
    Heinemann, L
    Linkeschova, R
    Rave, K
    Hompesch, B
    Sedlak, M
    Heise, T
    [J]. DIABETES CARE, 2000, 23 (05) : 644 - 649
  • [7] Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro
    Lepore, M
    Pampanelli, S
    Fanelli, C
    Porcellati, F
    Bartocci, L
    Di Vincenzo, A
    Cordoni, C
    Costa, E
    Brunetti, P
    Bolli, GB
    [J]. DIABETES, 2000, 49 (12) : 2142 - 2148
  • [8] Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes
    Pieber, TR
    Eugene-Jolchine, I
    Derobert, E
    [J]. DIABETES CARE, 2000, 23 (02) : 157 - 162
  • [9] A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes
    Raskin, P
    Klaff, L
    Bergenstal, R
    Hallé, JP
    Donley, D
    Mecca, T
    [J]. DIABETES CARE, 2000, 23 (11) : 1666 - 1671
  • [10] Less hypoglycemia with insulin glargine in intensive insulin therapy for the 1 diabetes
    Ratner, RE
    Hirsch, IB
    Neifing, JL
    Garg, SK
    Mecca, TE
    Wilson, CA
    [J]. DIABETES CARE, 2000, 23 (05) : 639 - 643